Vismodegib
Brand and Other Names:
Erivedge
Mechanism of Action:
Vismodegib is an inhibitor of the Hedgehog pathway. Vismodegib binds to and inhibits Smoothened, a transmembrane protein involved in Hedgehog signal transduction.
Indications:
ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation.
Route:
Oral
Dose:
The recommended dosage of ERIVEDGE is 150 mg taken orally once daily, with or without food, until disease progression or until unacceptable toxicity.
Adverse Reactions:
The most common adverse reactions (incidence of ≥ 10%) are muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, and ageusia.
Contraindication:
None
Warnings and Precautions:
Embryo-Fetal Toxicity, Severe Cutaneous Adverse Reactions, Musculoskeletal Adverse Reactions, Premature Fusion of the Epiphyses
See package insert for full prescribing information.